Genmab Rises After FDA Grants Breakthrough Therapy Status

Genmab A/S rose the most in almost two months after U.S. regulators granted “breakthrough therapy” designation to an experimental cancer drug the Danish company is developing with Johnson & Johnson.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.